Ali Raisuddin, Farah Abubakar, Binkhathlan Ziyad
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Saudi Pharm J. 2017 Feb;25(2):258-265. doi: 10.1016/j.jsps.2016.06.009. Epub 2016 Jul 1.
Tacrolimus is a potent immunosuppressant; however, it suffers from several problems such as poor water solubility (4-12 μg/mL), low and variable oral bioavailability in patients, and narrow therapeutic window that could not be solved by the currently available formulation (Prograf®). Moreover, Prograf® contains HCO-60 (PEGylated castor oil) as a surfactant, which is reported to cause several side effects including hypersensitivity reactions. Therefore, the aim of the present study was to investigate the potential of PEO--PCL polymeric micelles as alternative vehicles for the solubilization and delivery of tacrolimus. Four PEO--PCL block copolymers, with different molecular weights of PCL, were synthesized by ring opening polymerization of ε-caprolactone using methoxy polyethylene oxide (5,000 g mol) as initiator and stannous octoate as catalyst. Synthesized copolymers were characterized for their average molecular weights and polydispersity index by H NMR and gel permeation chromatography (GPC), respectively. Drug-free micelles of PEO--PCL were prepared through a co-solvent evaporation method using acetone as the organic co-solvent. Tacrolimus-loaded micelles were prepared using the same method with different initial amounts of drug. Prepared micelles were characterized for their mean diameter size and polydispersity of the micellar population by dynamic light scattering, and an HPLC assay was used to determine the encapsulation efficiency of tacrolimus. The average molecular weights of the synthesized copolymers were in the range of 8,400-28,000 with narrow distributions (PDI = 1.06-1.11). The copolymers were designated according to the degree of polymerization of ε-caprolactone, namely PEO--PCL, PEO--PCL, PEO--PCL, and PEO--PCL. All the prepared micelles were having diameters sizes less than 100 nm with narrow distributions. The highest drug solubilization was achieved with PEO--PCL, where the aqueous solubility of tacrolimus exceeded 300 μg/mL. Our results show a potential for PEO--PCL micelles as solubilizing vehicles for the delivery of tacrolimus.
他克莫司是一种强效免疫抑制剂;然而,它存在一些问题,如水溶性差(4 - 12μg/mL)、患者口服生物利用度低且变化大,以及治疗窗窄,而目前可用的制剂(普乐可复®)无法解决这些问题。此外,普乐可复®含有HCO - 60(聚乙二醇化蓖麻油)作为表面活性剂,据报道会引起多种副作用,包括过敏反应。因此,本研究的目的是研究聚环氧乙烷 - 聚己内酯(PEO - PCL)聚合物胶束作为他克莫司增溶和递送替代载体的潜力。使用甲氧基聚环氧乙烷(5000 g/mol)作为引发剂,辛酸亚锡作为催化剂,通过ε - 己内酯的开环聚合反应合成了四种具有不同聚己内酯分子量的PEO - PCL嵌段共聚物。分别通过核磁共振氢谱(H NMR)和凝胶渗透色谱法(GPC)对合成的共聚物的平均分子量和多分散指数进行了表征。采用丙酮作为有机共溶剂,通过共溶剂蒸发法制备了PEO - PCL的空白胶束。使用相同方法,采用不同初始药物量制备了载他克莫司胶束。通过动态光散射对制备的胶束的平均直径大小和胶束群体的多分散性进行了表征,并使用高效液相色谱法(HPLC)测定他克莫司的包封率。合成共聚物的平均分子量在8400 - 28000范围内,分布较窄(多分散指数PDI = 1.06 - 1.11)。根据ε - 己内酯的聚合度对共聚物进行了命名,即PEO - PCL、PEO - PCL、PEO - PCL和PEO - PCL。所有制备的胶束直径均小于100 nm,分布较窄。PEO - PCL实现了最高的药物增溶效果,他克莫司的水溶性超过300μg/mL。我们的结果表明,PEO - PCL胶束作为他克莫司递送的增溶载体具有潜力。